The role of rivaroxaban for patients with atherosclerotic vascular disease in the modern era

Catheter Cardiovasc Interv. 2021 May 1;97(6):1221-1229. doi: 10.1002/ccd.29089. Epub 2020 Jul 8.

Authors

Joshua C Vogt¹, Patrick G Manning², Omar Sheikh³, Herbert D Aronow², Robert J Chilton³, Joaquin E Cigarroa¹

Affiliations

¹ Division of Cardiology, Knight Cardiovascular Institute, Oregon Health and Science University, Portland, Oregon, USA.
² Division of Cardiology, Warren Alpert Medical School of Brown University, Lifespan Cardiovascular Institute, Providence, Rhode Island, USA.
³ Division of Cardiology, UT Health San Antonio, San Antonio, Texas, USA.

PMID: 32638540
DOI: 10.1002/ccd.29089

No abstract available

Keywords: atherosclerosis; coronary artery disease; drugs/pharmacotherapy; peripheral artery disease.

MeSH terms

Aspirin
Atherosclerosis* / drug therapy
Coronary Artery Disease*
Factor Xa Inhibitors / adverse effects
Humans
Rivaroxaban / adverse effects
Treatment Outcome

Substances

Factor Xa Inhibitors
Rivaroxaban
Aspirin